Stay updated on Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial
Sign up to get notified when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.

Latest updates to the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page
- Check7 days agoChange DetectedA new page revision v3.5.0 was added and the previous revision v3.4.3 was removed.SummaryDifference0.0%

- Check14 days agoChange DetectedRevision: v3.4.3 is now displayed, replacing the previous v3.4.2.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedAdded Revision: v3.4.2; removed the funding-status notice and Revision: v3.4.1 text.SummaryDifference0.4%

- Check50 days agoChange DetectedAdded a site-wide notice about a funding lapse and NIH Clinical Center operations, and updated the page version from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check57 days agoChange DetectedShow glossary toggle added to the page. Minor wording/capitalization changes were made to labels such as 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', and the revision tag updated to v3.4.0.SummaryDifference0.2%

- Check71 days agoChange DetectedThe page version was updated from v3.3.3 to v3.3.4, with Revision: v3.3.4 added and Revision: v3.3.3 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efprezimod Alfa as Immunomodulator in COVID-19 Clinical Trial page.